Detection of capecitabine (Xeloda®) on the skin surface after oral administration.
Palmoplantar erythrodysesthesia (PPE), or hand-foot syndrome, is a cutaneous toxicity under various chemotherapeutics contributing to the most frequent side effects in patients treated with capecitabine (Xeloda®). The pathomechanism of PPE has been unclear. Here, the topical detection of capecitabine in the skin after oral application was shown in 10 patients receiving 2500  mg/m 2 /day 2500  mg/m2/day capecitabine. Sweat samples were taken prior to and one week after oral administration of capecitabine. Using high-resolution continuum source absorption spectrometry, the changes in concentrations of fluorine, which is an ingredient of capecitabine, were quantified and statistically analyzed. Here, we show an increase in fluorine concentrations from 40±10  ppb 40±10  ppb (2±0.5  pM 2±0.5  pM ) before capecitabine administration to 27.7±11.8  ppm 27.7±11.8  ppm (14.6±6.5  nM 14.6±6.5  nM ) after application, p<0.001 p<0.001 . The results show the secretion of capecitabine on the skin surface after oral administration, indicating a local toxic effect as a possible pathomechanism of PPE.
Leibniz-Institut für Analytische Wissenschaften-ISAS-e. V., Albert-Einstein-Straße 9, 12489 Berlin, Germany.
Mao-Dong
MD
Huang
Helios Klinikum, Department of Hematology, Oncology and Palliative Care, Pieskower Street 33, 15526 Bad Saarow-Pieskow, Germany.
Harald
H
Fuss
Charité-Universitätsmedizin Berlin, Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venereology and Allergology, Charitéplatz1, 10117 Berlin, Germany.
Jürgen
J
Lademann
Leibniz-Institut für Analytische Wissenschaften-ISAS-e. V., Albert-Einstein-Straße 9, 12489 Berlin, Germany.
Stefan
S
Florek
Charité-Universitätsmedizin Berlin, Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venereology and Allergology, Charitéplatz1, 10117 Berlin, Germany.
Alexa
A
Patzelt
Charité-Universitätsmedizin Berlin, Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venereology and Allergology, Charitéplatz1, 10117 Berlin, Germany.
Martina C
MC
Meinke
Charité-Universitätsmedizin Berlin, Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venereology and Allergology, Charitéplatz1, 10117 Berlin, Germany.
Sora
S
Jung
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000069287:Capecitabine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D005461:Fluorine / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D012867:Skin / Q000737:chemistry*; D013057:Spectrum Analysis; D013542:Sweat / Q000737:chemistry*
D000964:Antimetabolites, Antineoplastic; D005461:Fluorine; D000069287:Capecitabine